<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190318043086N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-06-14</date_registration>
      <primary_sponsor>Babol University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Rosa Foetida Extract with Self-care behavior Education on Primary Dysmenorrhea</public_title>
      <acronym>ندارد</acronym>
      <scientific_title>The Effect of Rosa Foetida Extract with Self-care behavior Education on Primary Dysmenorrhea in Female Students of Babol University of Medical Sciences</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-05-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>135</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/38551</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: does not have, Randomization description: The subjects  are assigned to three groups by random blocking and  , Students are homogeneous according to body mass index, age of first menstruation and education, and mean score of severity of menstrual pain before treatment and educational actions, Blinding description: Study will be single blind. according to the coding the medicine packs the Participants who receiving will not be aware of the type of the medicine.,.</study_design>
      <phase>2</phase>
      <hc_freetext>Menstrual pain or Primary Dysmenorrhea.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Self-care behavior Education.This group will take  dysmenorrhea self-care behaviors classes as two-days  training sessions, the first and second part of the educational content in one day, and the third and fourth sections on the second day (60 to 90 minutes each day) as lectures and group discussion, practical demonstration. The content of the classes includes: - Anatomy and genital physiology education - Healthy  nutrition during menstruation - Isometric exercises - Tips during menstruation  - Relaxation techniques (relaxation and musical therapy and breathing) and heat and message therapy.  We will ask the students in the  group which got dysmenorrhea self care education only as intervention, that define their intensity of menstrual pain by visual analogue scale,1, 2, 4, 8, 12,24 hours after the start of their menstruation  in two consecutive menstrual cycles in the first two days of each cycle, and also complete the measure of menstrual distress and the scale of self-care behaviors in dysmenorrhea at the end of the second day. Intervention 2: Control group:Self-care education along placebo. In the training group along placebo in addition to dysmenorrhea self-care education, 200 mg of placebo capsules will be given every 8 hours in the first two days of the cycle for two consecutive cycles, and the intensity of pain will be defined on the visual analog scale.1, 2, 4, 8, 12, 24, 48 hours after the start of treatment. The menstrual distress scale and the dysmenorrhea scale of self-care behaviors in  at the end of the second day. Intervention 3: Intervention group: Dysmenorrhea Self-care education along Rosa foetida extract capsule.Capsules of Rosa foetida extract will be prepared in  Pharmacology Laboratory of Babol Medical School.In the training group along Rosa foetida extract in addition to dysmenorrhea self-care education, 200 mg of the extract capsules will be given every 8 hours in the first two days of the cycle for two consecutive cycles, and the intensity of pain will be defined on the visual analog scale.1, 2, 4, 8, 12, 24, 48 hours after the start of treatment. The menstrual distress scale and the dysmenorrhea scale of self-care behaviors in  at the end of the second day.Medications will be prepared in the form of placebo capsules and Rosa-foetida extract capsules. They will get coded in the same  envelopes, along with the prescription for taking the medicine. Pharmaceutical will be prepared with the help of a medicinal plants specialist in Babol University of Medical Sciences. The medicine will be prepared in the laboratory under  relevant rules. To do this, the fruit of Rosa foetida will get dried  then by milling to powder and then extracted with 70% ethanol by massaging, then the extract is dispersed using a rotary evaporator under low pressure solvent .The obtained extract will be kept in a freezer in- 21 ° C for the preparation of capsules.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hajar Pasha</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ganj Afrouz Avenue, Babol University of Medical Sciences, Mazandaran Province</address>
        <city>babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>47176-47754</zip>
        <telephone>+98 11 3219 7667</telephone>
        <email>dhajarpasha@gmail.com</email>
        <affiliation>Babol University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Shabnam Omidvar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of  Midwifery, Babol University of medical sciences, Ganj afrooz Street, Babol- Iran</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>47176-47745</zip>
        <telephone>+98 11 3219 9592</telephone>
        <email>sh.omidvar@mubabol.ac.ir</email>
        <affiliation>Babol University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Single girls have clinical symptoms of primary dysmenorrhea with pain score (5 or more) based on visual analog scale
Clinical symptoms of dysmenorrhea in at least 3 of 6 previous menstrual periods.
being single
Age of 18 to 24 years
Signing Consent Form
Body mass index  between 19 - 30
Regular cycles with duration of 21-  35 days
Length of bleeding 3- 7 days
Not having any menstrual cycle disorder during the 3 months before the study
Non-steroidal anti-inflammatory and anti-progestin at least a week before start of the period.
Non-use of hormonal drugs and oral contraceptives
Lack of special diet during the past 3 months
The desire to participate in the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>24 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Pain score less than 5 based on visual analog scale
History of genitourinary disease or history of abdominal and pelvic surgery
History of blood diseases
stomach ache
Disorders of the kidney function
Stressful accidents over the past six months
Discontinue drug use
History of allergic diseases
History of allergy to medicinal herbs
History of allergy with non-steroidal anti-inflammatory drugs
Taking supplements and vitamins
Unwilling to continue study
incomplete questionnaire
Probable event of complications
History of a prominent physical and psychological problem.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N94.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Primary dysmenorrhea</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Lifestyle</i_code>
      <i_code>Placebo</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Self-care behavior Education.This group will take  dysmenorrhea self-care behaviors classes as two-days  training sessions, the first and second part of the educational content in one day, and the third and fourth sections on the second day (60 to 90 minutes each day) as lectures and group discussion, practical demonstration. The content of the classes includes: - Anatomy and genital physiology education - Healthy  nutrition during menstruation - Isometric exercises - Tips during menstruation  - Relaxation techniques (relaxation and musical therapy and breathing) and heat and message therapy.  We will ask the students in the  group which got dysmenorrhea self care education only as intervention, that define their intensity of menstrual pain by visual analogue scale,1, 2, 4, 8, 12,24 hours after the start of their menstruation  in two consecutive menstrual cycles in the first two days of each cycle, and also complete the measure of menstrual distress and the scale of self-care behaviors in dysmenorrhea at the end of the second day.</i_keyword>
      <i_keyword>Control group:Self-care education along placebo. In the training group along placebo in addition to dysmenorrhea self-care education, 200 mg of placebo capsules will be given every 8 hours in the first two days of the cycle for two consecutive cycles, and the intensity of pain will be defined on the visual analog scale.1, 2, 4, 8, 12, 24, 48 hours after the start of treatment. The menstrual distress scale and the dysmenorrhea scale of self-care behaviors in  at the end of the second day.</i_keyword>
      <i_keyword>Intervention group: Dysmenorrhea Self-care education along Rosa foetida extract capsule.Capsules of Rosa foetida extract will be prepared in  Pharmacology Laboratory of Babol Medical School.In the training group along Rosa foetida extract in addition to dysmenorrhea self-care education, 200 mg of the extract capsules will be given every 8 hours in the first two days of the cycle for two consecutive cycles, and the intensity of pain will be defined on the visual analog scale.1, 2, 4, 8, 12, 24, 48 hours after the start of treatment. The menstrual distress scale and the dysmenorrhea scale of self-care behaviors in  at the end of the second day.Medications will be prepared in the form of placebo capsules and Rosa-foetida extract capsules. They will get coded in the same  envelopes, along with the prescription for taking the medicine. Pharmaceutical will be prepared with the help of a medicinal plants specialist in Babol University of Medical Sciences. The medicine will be prepared in the laboratory under  relevant rules. To do this, the fruit of Rosa foetida will get dried  then by milling to powder and then extracted with 70% ethanol by massaging, then the extract is dispersed using a rotary evaporator under low pressure solvent .The obtained extract will be kept in a freezer in- 21 ° C for the preparation of capsules.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Intensity of pain. Timepoint: 1،2، 4، 8، 12، 24، 48 The hour after the onset of menstrual pain. Method of measurement: Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Menstrual distress score. Timepoint: One month before the intervention During the first two days of menstruation and in two Consecutive cycles. Method of measurement: Menstrual distress scales.</sec_outcome>
      <sec_outcome>Menstrual bleeding severity. Timepoint: One month before the intervention  in two Consecutive cycles. Method of measurement: Pictorial Schedule Questionnaire.</sec_outcome>
      <sec_outcome>Side effects. Timepoint: During two cycles of taking drug. Method of measurement: Ask the participant.</sec_outcome>
      <sec_outcome>Number of absent days of class. Timepoint: One month before the intervention and two consecutive cycles. Method of measurement: Ask the participant.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Babol University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-01-29</approval_date>
        <contact_name>Ethics committee of Babol University of Medical Sciences</contact_name>
        <contact_address>Babol University of Medical Sciences, Ganj Afroz Street, babol, mazandaran babol Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
